Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$6.83 USD
+0.51 (8.07%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $6.83 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Amicus Therapeutics, Inc. has a market cap of $2.11B, which represents its share price of $6.83 multiplied by its outstanding shares number of 308.24M. As a mid-cap company, FOLD's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FOLD 6.83 +0.51(8.07%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
New Strong Sell Stocks for June 3rd
Other News for FOLD
JPMorgan Increases Price Target for Amicus Therapeutics (FOLD)
Amicus price target raised by $2 at JPMorgan, here's why
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ...
Q2 2025 Amicus Therapeutics Inc Earnings Call Transcript
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200